EVT LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.3 AUD | 0.00% |
|
+0.80% | -7.60% |
| Apr. 30 | Evotec, Bayer to Focus on Precision Treatments for Cardiovascular Diseases | MT |
| Apr. 24 | Germany's Evotec Appoints Permanent CEO | MT |
Valuation
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,008 | 1,356 | 2,038 | 2,104 | 1,894 | 1,834 | - | - |
| Enterprise Value (EV) 1 | 2,313 | 2,468 | 357,250 | 2,315 | 3,085 | 3,067 | 3,072 | 3,052 |
| P/E ratio | 18.1 x | -118 x | -42.4 x | 39.7 x | 17.9 x | 69.4 x | 24.1 x | 18.9 x |
| Yield | 4.16% | 2.5% | - | - | 3.92% | 1.24% | 2.84% | 3.44% |
| Capitalization / Revenue | 1.99 x | 1.73 x | 2.94 x | 2.13 x | 1.48 x | 1.56 x | 1.4 x | 1.31 x |
| EV / Revenue | 2.29 x | 3.15 x | 516 x | 2.34 x | 2.42 x | 2.6 x | 2.34 x | 2.18 x |
| EV / EBITDA | 10.1 x | 9.86 x | 13,124 x | 16.7 x | 9.47 x | 10.6 x | 8.67 x | 7.85 x |
| EV / FCF | 48.7 x | 47.9 x | 2,914 x | 13 x | 74.6 x | 65.5 x | 36 x | 20.2 x |
| FCF Yield | 2.05% | 2.09% | 0.03% | 7.67% | 1.34% | 1.53% | 2.78% | 4.95% |
| Price to Book | 1.79 x | 1.39 x | 2.34 x | 2.3 x | 1.88 x | 1.85 x | 1.75 x | 1.67 x |
| Nbr of stocks (in thousands) | 160,656 | 161,196 | 161,196 | 161,196 | 161,328 | 162,296 | - | - |
| Reference price 2 | 12.50 | 8.410 | 12.64 | 13.05 | 11.74 | 11.30 | 11.30 | 11.30 |
| Announcement Date | 8/22/19 | 8/31/20 | 8/22/21 | 8/21/22 | 8/27/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,009 | 784.1 | 692.5 | 987.8 | 1,275 | 1,179 | 1,311 | 1,403 |
| EBITDA 1 | 229.1 | 250.3 | 27.22 | 138.3 | 325.9 | 290.6 | 354.4 | 388.9 |
| EBIT 1 | 158.9 | 55.67 | -51.06 | 61.49 | 141.3 | 98.82 | 160.1 | 191.3 |
| Operating Margin | 15.75% | 7.1% | -7.37% | 6.23% | 11.08% | 8.38% | 12.21% | 13.64% |
| Earnings before Tax (EBT) 1 | 149.1 | -47.98 | -63.03 | 53.82 | 156.1 | 52.74 | 104.7 | 133.9 |
| Net income 1 | 111.9 | -11.37 | -48.04 | 53.32 | 106.5 | 25.33 | 73.8 | 96.46 |
| Net margin | 11.09% | -1.45% | -6.94% | 5.4% | 8.35% | 2.15% | 5.63% | 6.88% |
| EPS 2 | 0.6910 | -0.0710 | -0.2980 | 0.3290 | 0.6550 | 0.1629 | 0.4693 | 0.5966 |
| Free Cash Flow 1 | 47.5 | 51.54 | 122.6 | 177.6 | 41.37 | 46.81 | 85.39 | 151.2 |
| FCF margin | 4.71% | 6.57% | 17.7% | 17.98% | 3.24% | 3.97% | 6.51% | 10.78% |
| FCF Conversion (EBITDA) | 20.74% | 20.59% | 450.37% | 128.44% | 12.69% | 16.11% | 24.09% | 38.87% |
| FCF Conversion (Net income) | 42.45% | - | - | 333.14% | 38.84% | 184.76% | 115.69% | 156.72% |
| Dividend per Share 2 | 0.5200 | 0.2100 | - | - | 0.4600 | 0.1396 | 0.3215 | 0.3890 |
| Announcement Date | 8/22/19 | 8/31/20 | 8/22/21 | 8/21/22 | 8/27/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: June | 2020 S1 | 2020 S2 | 2021 S1 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 | 2025 S1 | 2025 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 526.1 | 258 | 294.1 | 438 | 519.4 | 606.8 | 668.6 | 658.9 | 501.9 | - | - |
| EBITDA | - | 87.44 | -31.06 | - | 74.26 | - | - | 96.09 | - | - | - |
| EBIT | - | -39.63 | -73.09 | 20.88 | 40.62 | - | - | 68.88 | - | - | - |
| Operating Margin | - | -15.36% | -24.85% | 4.77% | 7.82% | - | - | 10.46% | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | 39.27 | - | - | - |
| Net income | - | - | -60.22 | 33.3 | 19.98 | 96.74 | 9.791 | 27.1 | - | - | - |
| Net margin | - | - | -20.48% | 7.6% | 3.85% | 15.94% | 1.46% | 4.11% | - | - | - |
| EPS 2 | - | - | -0.3740 | 0.2050 | - | 0.5930 | 0.0620 | 0.1670 | 0.2300 | 0.3900 | 0.2700 |
| Dividend per Share 2 | - | - | - | - | - | - | 0.2000 | 0.1400 | - | - | - |
| Announcement Date | 2/20/20 | 8/31/20 | 2/18/21 | 2/20/22 | 8/21/22 | 2/19/23 | 8/27/23 | 2/15/24 | - | - | - |
1AUD in Million2AUD
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 305 | 1,113 | 355,212 | 211 | 1,191 | 1,233 | 1,238 | 1,218 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 1.333 x | 4.446 x | 13,049 x | 1.527 x | 3.655 x | 4.242 x | 3.494 x | 3.133 x |
| Free Cash Flow 1 | 47.5 | 51.5 | 123 | 178 | 41.4 | 46.8 | 85.4 | 151 |
| ROE (net income / shareholders' equity) | 10.1% | 1.71% | -6.02% | 5.95% | 6.48% | 2.61% | 7.46% | 9.57% |
| ROA (Net income/ Total Assets) | 6.36% | 0.8% | -2.04% | 2.02% | 2.34% | 2.93% | 3.69% | 4.44% |
| Assets 1 | 1,759 | -1,416 | 2,355 | 2,644 | 4,548 | 864.6 | 2,002 | 2,174 |
| Book Value Per Share 2 | 6.990 | 6.050 | 5.410 | 5.680 | 6.260 | 6.110 | 6.450 | 6.770 |
| Cash Flow per Share 2 | 1.060 | 1.090 | 0.9200 | 1.730 | 1.490 | 1.220 | 1.610 | 1.770 |
| Capex 1 | 119 | 125 | 29.2 | 99.5 | 200 | 134 | 147 | 151 |
| Capex / Sales | 11.77% | 15.92% | 4.22% | 10.07% | 15.71% | 11.33% | 11.24% | 10.75% |
| Announcement Date | 8/22/19 | 8/31/20 | 8/22/21 | 8/21/22 | 8/27/23 | - | - | - |
1AUD in Million2AUD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
11.3
AUD
Average target price
13.12
AUD
Spread / Average Target
+16.13%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.60% | 1.24B | |
| -14.82% | 3.32B | |
| -14.87% | 1.92B | |
| -12.30% | 1.7B | |
| -.--% | 1.19B | |
| -26.04% | 1.15B | |
| -15.56% | 1.17B | |
| -20.81% | 1.02B | |
| -.--% | 818M | |
| -2.94% | 672M |
- Stock Market
- Equities
- EVT Stock
- Financials EVT Limited
